Management of gout in older adults: Barriers to optimal control

Drugs and Aging

Volumn 24, Issue 1, 2007, Pages 21-36

  Hoskison, Karl T ^a   Wortmann, Robert L ^a  

^a University of Oklahoma Tulsa College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMOXICILLIN; AMPICILLIN; BENZBROMARONE; CELECOXIB; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DICLOFENAC; ETORICOXIB; FEBUXOSTAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROBENECID; PROTON PUMP INHIBITOR; SULFINPYRAZONE; TRIAMCINOLONE; URATE; URICOSURIC AGENT;

ABDOMINAL DISCOMFORT; AGING; ALCOHOL CONSUMPTION; ALOPECIA; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ASEPTIC MENINGITIS; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONFUSION; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEATH; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPEPSIA; FEVER; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTION; JAUNDICE; JOINT SWELLING; KIDNEY FAILURE; NAUSEA; NEUROPATHY; OBESITY; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; REVIEW; RHABDOMYOLYSIS; SARCOIDOSIS; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT CONTRAINDICATION; VASCULITIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GOUT; GOUT SUPPRESSANTS; HORMONES; HUMANS; PATIENT COMPLIANCE;

EID: 33846403715     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724010-00002     Document Type: Review

References (104)

1. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout [abstract]. Arthritis Res Ther 2006; 8 Suppl. 1: S2
2. Mikuls TR, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005; 44: 1038-42
3. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: 1582-7
4. Guyer B, Freedman MA, Strobino DM, et al. Annual summary of vital statistics: trends in health of Americans during the 20th century. Pediatrics 2000; 106: 1307-17
5. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults 1992-2000. JAMA 2002; 288: 1723-17
6. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206
7. Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with various components of insulin resistance syndrome in young black and white adults: the CARDIA study. Ann Epidemiol 1998; 8: 250-61
8. Choi H, Adkinson K, Karlson E, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men. Arch Intern Med 2005; 165: 742-8
9. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72
10. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000; 43: 103-8
11. Ene-Stroescu D, Gorbien MJ. Gouty arthritis: a primer of late-onset gout. Geriatrics 2005 (Jul); 60: 24-31
12. Schlesinger N, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol 2001; 13: 240-4
13. Schlesinger N, Baker DG, Schumacher HR Jr. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol 1999; 11: 441-5
14. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004; 50 (3): 937-43
15. Schumacher HR Jr, Edwards NL, Perez-Ruiz F, et al. Outcome measures for acute and chronic gout. J Rheumatol 2005; 32: 2452-5
16. Zhang W, Doherty M, Pascual E, et al. EULAR evidenced based report recommendations for gout. Part 1: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006 Oct; 65 (10): 1310-11. Epub 2006 May 17
17. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendation for gout. Part II: management report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006 Oct; 65 (10): 1312-24. Epub 2006 May 17
18. Park YB, Park YS, Lee WK, et al. Clinical manifestations of Korean female gouty patients. Clin Rheumatol 2000; 19: 142-6
19. Townshend D, Vasu P. Gouty tenosynovitis - more common than we think? N Z Med J 2004; 117: 1188
20. Kini S, Mittal G, Balakrishna C, et al. An unusual systemic presentation of gout. J Assoc Physicians India 2000; 48: 354-5
21. Symons MCR. Self-treatment of gout. Med Hypothesis 2001; 57: 241-2
22. Hunter DJ, York M, Chaisson CE, et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006; 33: 1341-5
23. Wortmann RL. Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field. Curr Rheumatol Rep 2004; 6: 235-9
24. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of gouty arthritis. BMJ 2002; 324: 1488-92
25. Dieppe PA. Investigation and management of gout in the young and the elderly. Ann Rheum Dis 1991; 50: 263-6
26. Fendrick AM, Garabedian-Ruffalo SM. A clinician's guide to the selection of NSAID therapy. Pharm Ther 2002; 27: 579-82
27. Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy: classical indications and new therapeutic uses. Eur J Med Res 2001; 6: 150-60
28. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep 2002; 4: 252-6
29. Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine - guidelines for use. J Rheumatol 1988; 15: 495-9
30. Evans TI, Wheeler MT, Small RE, et al. A comprehensive investigation of inpatient colchicine use shows more education is needed. J Rheumatol 1996; 23: 143-9
31. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17: 301-4
32. Kim KY, Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003; 25: 1593-617
33. Iacobuzio-Donahue CA, Lee EL, Abraham SC, et al. Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. Am J Surg Path 2001; 25: 1067-70
34. Chattopadhyay I, Shetty HMG, Routledge PA, et al. Colchicine induced rhabdomyolysis. Postgrad Med J 2001; 77: 191-4
35. Simkin P, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol 2000; 27: 1334-7
36. Pirzada NA, Medell M, Ali II. Colchicine induced neuromyopathy in a patient with normal renal function. J Clin Rheumatol 2001; 7: 374-6
37. Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111-3
38. Terkeltaub RA. Gout. N Engl J Med 2003; 349: 1647-55
39. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329-36
40. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11: 974-9
41. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994; 21: 1325-7
42. Wyngaarden JB, Kelley WN. Gout and hyperuricemia. New York (NY): Grune & Stratton, 1976
43. Fernandez C, Naguera R, Gonzalez JA, et al. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26: 2285-6
44. Rull M, Clayborne G, Sieck M, et al. Intraarticular corticosteroid preparations: different characteristics and their effect during inflammation induced by monosodium urate crystals in the rat subcutaneous air pouch. Rheumatology 2003; 42: 1093-100
45. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 33: 803-5
46. Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21: 696-9
47. Getting SJ, Christian HC, Flower RJ, et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002; 46: 2765-75
48. Gutman AB. Gout. In: Beeson PB, McDermott W, editors. Textbook of medicine. 12th ed. Philadelphia (PA): WB Saunders, 1958: 595
49. Nakayama DA, Barthelemy C, Carrera G, et al. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984; 27: 468-73
50. McCarthy GM, Barthelemy CR, Veum JA, et al. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991; 34: 489-95
51. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989; 16: 1246-8
52. Van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of long-term antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993; 20: 1383-5
53. Pascual E, Battle-Gualda E, Martinez A, et al. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med 1999; 131: 756-9
54. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577-80
55. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321-5
56. Palella TD, Kelley WN. An approach to hyperuricemia and gout. Geriatrics 1984; 39: 89-102
57. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995; 22: 908-14
58. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel non purine selective inhibitor of xanthine oxidase. Arthritis Rheum 2005; 52: 916-23
59. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat versus allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-61
60. Wallace S, Singer J, Duncan G, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991; 18: 264-9
61. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis: prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 1961; 55: 179-86
62. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophic in chronic gout. Arthritis Rheum 2002; 47: 356-60
63. Harris M, Bryant LR, Danaher P, et al. Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. J Rheumatol 2000; 27: 2873-6
64. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545-9
65. Perez-Ruiz F, Calabozo C, Herrero-Betes A, et al. Improvement in renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2002; 86: 287-92
66. Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, et al. Long-term efficacy of hyperuricemia treatment in renal transplant patients. Nephrol Dial Transplant 2003; 18 (3): 603-6
67. Wortman RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14: 281-6
68. Schumacher HR, Becker MA, Wortmann RL, et al. Febuxostat versus allopurinol and placebo in subjects with hyperuricemia and gout [abstract]. Arthritis Rheum 2005; 52 Suppl.: S680
69. Perez-Ruiz F, Hernando I, Villar I, et al. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J Clin Rheumatol 2005 Jun; 11 (3): 129-33
70. Hande KR, Noone RM, Stone WI. Severe allopurinol toxicity: description and guidelines for presentation in patients with renal insufficiency. Am J Med 1984; 76: 47-53
71. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33: 1646-50
72. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-7
73. Fam AG, Dunne SM, Iazzitta J, et al. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001; 44: 231-8
74. Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 2001; 3: 29-35
75. Raman G, Sharman V, Lee H. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med 1990; 228: 69-71
76. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostal: a novel non-purine selective inhibitor of xanthine oxidase in allopurinol intolerant patients [abstract]. Arthritis Rheum 2004; 50: 9 Suppl.: S336
77. Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyene glycol (uricase-PEG 20): biochemical rational and preclinical studies. J Rheumatol 2002; 29: 1942-9
78. Ganson NJ, Kelley SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against polyethylene glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase [abstract]. Arthritis Res Ther 2005; 8: R12
79. Choi H, Atkinson KK, Karlson E, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277-81
80. Ghany M, Hoofnagle JH. Approach to the patient with liver disease. In: Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison's principles of internal medicine. 16th ed. New York (NY): McGraw Hill, 2005: 1808-12
81. Moore AA, Giuli L, Gould R, et al. Alcohol use, comorbidity, and mortality. J Am Geriatr Soc 2006; 54: 757-62
82. Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998; 32: 917-25
83. Dessein PH, Shipton EA, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539-48
84. Choi HK, Liu S. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 52 (1): 283-9
85. Fam AG. Gout, diet and the insulin resistance syndrome. J Rheumatol 2002; 29: 1350-6
86. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 2001; 28: 2294-7
87. Tenenbaum A, Fisman EZ, Boyko V, et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006; 166: 737-41
88. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blockers vs. diuretics. JAMA 2002; 288: 2981-97
89. Minghelli G, Seydoux C, Goy JJ, et al. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998; 66: 268-71
90. Wurzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2001; 19: 1855-60
91. Stamp L, Sharples K, Gow P, et al. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 2000; 30: 567-72
92. Mikuls TR, Curtis JR, Allison JJ, et al. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national anonymous internet-accessible error reporting system. J Rheumatol 2006; 33: 562-6
93. Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med 1978; 88: 666-70
94. Wortmann RL. The treatment of gout: the use of an analogy. Am J Med 1998; 105: 513-6
95. Wannamethee SG, Sharper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78: 147-53
96. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51
97. Baker JF, Krishnan E, Chen L, et al. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005; 118: 816-26
98. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-Up Study. Am J Epidemiol 1995; 141: 637-44
99. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risks for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13
100. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006; 54: 2688-96
101. Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66: 281-7
102. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140 (3): 167-74
103. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350 (23): 2362-74
104. Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 2004; 164 (10): 1092-7